Tayahop, Kianna .

HRN: 27-66-40  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/02/2025
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
10/02/2025
10/08/2025
IVTT
65mg
IVTT
Sepsis; R/o CNS Infection
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Bloodstream    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: